Skip to main
DMAC
DMAC logo

DMAC Stock Forecast & Price Target

DMAC Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

DiaMedica Therapeutics Inc. has reported encouraging interim Phase 2 results in its clinical program for preeclampsia, highlighting a statistically significant reduction in blood pressure without placental transfer, which strengthens the prospects for its product candidate DM199. This positive data has led to an increased price target, reflecting improved market confidence and the potential for substantial advancements in both preeclampsia and acute ischemic stroke treatment pathways. Furthermore, the favorable outcomes position DM199 favorably for future cohort enrollments, reinforcing the company's development strategy and prospects for future growth.

Bears say

DiaMedica Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock. Key concerns include the potential inability of its developmental candidates, DM199 and DM300, to meet projected peak commercial revenue estimates, which could stem from factors such as limited market size and penetration rates. Additionally, the company may struggle to secure adequate capital to fund ongoing operations and development, further complicating prospects for commercialization of its therapies.

DMAC has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DiaMedica Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DiaMedica Therapeutics Inc (DMAC) Forecast

Analysts have given DMAC a Strong Buy based on their latest research and market trends.

According to 3 analysts, DMAC has a Strong Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DiaMedica Therapeutics Inc (DMAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.